JIN 002
Alternative Names: Histone deacetylase inhibitor - J Ints Bio; JIN-002Latest Information Update: 28 Jun 2024
At a glance
- Originator Joseah Biopharma
- Developer J Ints Bio
- Class Antineoplastics
- Mechanism of Action HDAC6 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Glioblastoma
- Discontinued Peripheral T-cell lymphoma
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for preclinical development in Glioblastoma in Taiwan
- 13 Feb 2023 Discontinued - Phase-I for Peripheral T-cell lymphoma in Taiwan (unspecified route) (J Ints Bio Pipeline, February 2023)
- 25 Sep 2022 JIN 002 is available for licensing as of 22 Jun 2022. https://jintsbio.com/about-us?tab=PARTNERSHIP